Christopher D. Ozeroff
Equibles does not estimate personal net worth.
About Christopher D. Ozeroff
Earlier roles on record: General Counsel at Oruka Therapeutics, Inc. (ORKA) until March 31, 2023. Oruka Therapeutics, Inc. reported in an 8-K filed February 13, 2023 that Christopher D. Ozeroff was terminated as Secretary, Senior Vice President and General Counsel, effective March 31, 2023. The proxy statement of Oruka Therapeutics, Inc. reports total compensation of $316,429 for Christopher D. Ozeroff in fiscal 2022, including a base salary of $304,000. Disclosed compensation is on record for 5 fiscal years.
“ARCA biopharma, Inc. (“ARCA” or the "Company") and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023.”
Affiliation history
-
Start not stated–2023-03-31
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Oruka Therapeutics, Inc. (ORKA) | Former Secretary, Senior Vice President and General Counsel | $304,000 | $316,429 |
| 2021 | Oruka Therapeutics, Inc. (ORKA) | Former Secretary, Senior Vice President and General Counsel | $303,744 | $366,029 |
| 2020 | Oruka Therapeutics, Inc. (ORKA) | Secretary, Senior Vice President and General Counsel | $279,617 | $555,848 |
| 2019 | Oruka Therapeutics, Inc. (ORKA) | Secretary, Senior Vice President and General Counsel | $277,901 | $290,157 |
| 2018 | Oruka Therapeutics, Inc. (ORKA) | Secretary, Senior Vice President and General Counsel | $297,343 | $310,257 |